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Abstract
Objectives: Decrements in cognitive function may already be evident in young children with type 1 diabetes (T1D).
Here we report prospectively acquired cognitive results over 18 months in a large cohort of young children with and
without T1D. Methods: A total of 144 children with T1D (mean HbA1c: 7.9%) and 70 age-matched healthy controls
(mean age both groups 8.5 years; median diabetes duration 3.9 years; mean age of onset 4.1 years) underwent
neuropsychological testing at baseline and after 18-months of follow-up. We hypothesized that group differences
observed at baseline would be more pronounced after 18 months, particularly in those T1D patients with greatest
exposure to glycemic extremes. Results: Cognitive domain scores did not differ between groups at the 18 month testing
session and did not change differently between groups over the follow-up period. However, within the T1D group, a
history of diabetic ketoacidosis (DKA) was correlated with lower Verbal IQ and greater hyperglycemia exposure (HbA1c
area under the curve) was inversely correlated to executive functions test performance. In addition, those with a history of
both types of exposure performed most poorly on measures of executive function. Conclusions: The subtle cognitive
differences between T1D children and nondiabetic controls observed at baseline were not observed 18 months later.
Within the T1D group, as at baseline, relationships between cognition (Verbal IQ and executive functions) and glycemic
variables (chronic hyperglycemia and DKA history) were evident. Continued longitudinal study of this T1D cohort and
their carefully matched healthy comparison group is planned. (JINS, 2016, 22, 293–302)
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INTRODUCTION
Children with early onset diabetes (EOD; <5 years of age at
diagnosis) are more likely than those with later onset to have
poorer cognitive outcomes in the domains of IQ (Northam
et al., 1998; Rovet, Whelixh, & Hoppe, 1987), executive
functions (Bjorgaas, Gimse, Vik, & Sand, 1997; Flykanaka-
Gantenbein, 2004; Lin, Northam, Rankins, Werther, &
Cameron, 2010; Ly, Anderson, McNamara, Davis, & Jones,
2011), learning and memory (Gaudieri, Chen, Greer, &
Holmes, 2008; Lin et al., 2010), and processing speed
(Lin et al., 2010; Northam et al., 2001; Ryan, Vega, & Drash,
1985). One or more severe hypoglycemia episodes
Correspondence and reprint requests to: M. Allison Cato, Nemours
Children’s Health System, Neurology Division, 807 Children’s Way,
Jacksonville, FL 32207. E-mail: acato@nemours.org
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(with seizure or loss of consciousness) in childhood has also
been associated with poorer cognitive outcomes (Blasetti
et al., 2011; Hershey, Craft, Bhargaava, & White, 1997;
Hershey, Lillie, Sadler, & White, 2003, 2004; Hershey et al.,
2005; Lin et al., 2010; Naguib, Kulinskaya, Lomax, &
Garralda, 2009; Northam et al., 2001; Perantie et al., 2008;
Rovet & Ehrlich, 1999) and brain volume differences
(Ferguson et al., 2003; Haumont, Dorchy, & Pelc, 1979;
Hyllienmark, Maltez, Dandenell, Luvigsson, & Brismar,
2005; Musen et al., 2006; Northam et al., 2009; Perantie
et al., 2011, 2007; Perros, Deary, Sellar, Best, & Frier, 1997).
Chronic hyperglycemia may also interfere with brain
functioning and cognition. Greater hyperglycemia exposure
has been associated with differences in gray and white matter
volumes (Perantie et al., 2011, 2007), lower processing speed
(Jacobson et al., 2011), and lower verbal intelligence
(Perantie et al., 2008) in EOD boys only (Schoenle et al.,
2002). In our previously reported baseline analyses in the
same cohort as reported here, greater hyperglycemia before
the baseline evaluation was associated with differences in
gray matter volumes in frontal, temporal, and other posterior
cortical regions (Marzelli et al., 2014). Baseline neuroima-
ging also revealed widespread white matter differences in
T1D youth, more so in those with longer disease duration and
greater recent exposure to hyperglycemia (Barnea-Goraly
et al., 2014).
Investigators have speculated that there may also be
interactions between age and degree of exposure to glycemic
extremes, with the most vulnerable children being those
with early childhood onset of T1D and a history of
chronic hyperglycemia or severe hypoglycemia (Arbelaez,
Semenkovich, & Hershey, 2013). Some support for this
concept has come from a cross sectional analysis of school-age
children, demonstrating that early exposure to severe
hypoglycemia was associated with lower memory performance
(Hershey et al., 2005). In addition, there has been speculation
that early exposure to extreme glycemic states (e.g., DKA at
diagnosis) may predispose children to poor outcomes in the
case of subsequent prolonged and more severe dysglycemia
(e.g., chronic hyperglycemia, Ryan, 2006).
Cross-sectional studies, however, cannot adequately test
such complex hypotheses, control for baseline differences or
support causal inferences. Thus, prospective longitudinal
follow-up is necessary to understand the impact of various
degrees of glycemic exposure and their interactions with age.
Our ongoing longitudinal study of young children with and
without T1D aims to address this question using cognitive
and neuroimaging tools. We recently reported that young
children with T1D have a different developmental trajectory
over 18 months in gray and white matter volumes compared
to non-diabetic controls and that these differences strongly
correlated with the degree of hyperglycemia experienced
during an 18-month follow-up period. Speciﬁcally, T1D
youth had slower grey matter development in widespread
regions including left precuneus extending to left parietal and
occipital cortex and right frontal, temporal, and parietal lobes.
White matter growth was also slower across anterior, inferior
frontal, and superior parietal regions. The strongest effect on
white matter growth was observed in a right anterior frontal
region near the corpus callosum. Among T1D youth, greater
extent of overall disease-related exposure to hyperglycemia
related inversely to gray matter growth in widespread
regions. Higher glucose variability was also associated with
slower rates of growth across widespread grey and white
matter regions (Mauras et al., 2015).
In the same cohort at baseline, we reported subtle cognitive
differences between children (4 to <10 years old) with T1D
compared to healthy age-matched controls (Cato et al., 2014).
While the group differences did not meet stringent statistical
signiﬁcance thresholds after adjusting for multiple compar-
isons and correction for parent IQ; child IQ and Executive
Functions domain scores trended lower in those with T1D
(both p = .02) (Cato et al., 2014). Furthermore, degree of
previous hyperglycemia (as measured by several indices
derived by HbA1c values and continuous glucose monitoring
[CGM] data) was associated with these differences (Cato
et al., 2014). Chronic hyperglycemia in T1D youth, indexed
by averaged A1c area under the curve (AUC) above 6.0% was
associated with lower IQ (p = .05). The percentage of time
blood glucose (BG) level exceeded 180mg/dL was associated
with a lower Executive Functions domain score (p = .04). The
next logical step, reported in this study, is to determine how
cognitive performance changes over time in T1D versus
controls and whether these changes correlate with glycemic
exposure during follow-up. In this ongoing, prospective,
well-controlled, large-scale longitudinal study we have a
unique opportunity to determine the timeframe, risk factors,
and effect of cumulative exposure to glycemic extremes
beginning in early childhood. We hypothesized that cognitive
differences between groups would become more clearly
pronounced over time. We also hypothesized that exposure to
dysglycemia and severe metabolic events [severe hypoglyce-
mia (SH), diabetic ketoacidosis (DKA)] during the follow-up
period would be associated with worse cognitive outcomes.
METHODS
All human data included in this manuscript were obtained
after institutional review approval at each of the participating
centers and informed written consent obtained from parents
or guardians and child assent when appropriate.
Participants
A total of 144 children with T1D and 72 non-diabetic con-
trols participated in the study at baseline (Cato et al., 2014).
From this cohort, all 144 children with T1D and 70 of the
non-diabetic participants completed at least a portion of the
18-month cognitive testing and follow-up. The T1D and
control groups had similar gender distributions, parental
education and family income levels. At 18-months
follow-up, average age was 8.5 years for both groups
(range, 5.4 to 11.5 years). The T1D cohort had a median
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duration of diabetes of 3.9 years, ranging from 1.6 to
9.5 years. Mean age of onset was 4.1 years (range, 0.9 to
8.0 years), with 67% (N = 97) diagnosed before age ﬁve.
A comprehensive summary of demographic characteristics of
each group was summarized in the baseline study. The T1D
and control groups had similar gender distributions, parent
education and income levels (Cato et al., 2014, Table 2).
Among children with T1D, 16% (n = 23) had a history of at
least one episode of severe hypoglycemia and 36% (n = 51)
had a history of DKA before the baseline study, while 4%
(n = 6) had at least one episode of severe hypoglycemia and
3% (n = 4) had a history of DKA between the baseline study
and the 18-month follow-up study.
Glycemic Control
Methods to ascertain glycemic control among the T1D par-
ticipants were previously described (Cato et al., 2014).
HbA1c values were collected every 3 months for the
18 months of the study. For participants using an unblinded
personal CGM as part of their diabetes care data were col-
lected every 3 months for the 18 months of the study.
Otherwise, participants were asked to use a blinded CGM
(iPro2®, Medtronic MiniMed, Northridge, CA or DexCom
SEVEN Plus®, DexCom, San Diego, CA) for 6 days every
3 months to collect at least 72 hr of CGM data with at least
24 hr of data overnight (10 p.m. to 6 a.m.).
Neurocognitive Testing
The neurocognitive testing methods have been previously
described in detail (Cato et al., 2014). Table 1 lists test battery
by domains assessed. In keeping with the literature, the
battery was selected to cover the cognitive domains of interest:
IQ, Executive Functions, Learning and Memory, and Proces-
sing Speed using age-appropriate measures. The assignment
of tasks to each cognitive domain was based on clinical
experience. At baseline, one of the parents completed an IQ
measure to be used as a planned covariate. Parent-reported
externalizing behavior, internalizing mood symptoms, and
executive functioning ratings were also obtained.
The same monitoring of BG concentrations was conducted
for the 18-month follow-up. Acceptable BG concentration
range was between 70 and 300mg/dL during testing. Ketones
were evaluated in cases of BG> 300mg/dL and if more than
trace urine ketones or blood ketones ≥ 0.6mmol/L were
present, testing was postponed. Testing was also suspended if
BG dropped below 70mg/dL. BG levels were checked
at least twice during the evaluation at regular, planned
intervals, by ﬁngerstick on a home glucose meter. Test
protocols were double scored at a centralized location
Table 1. Neurocognitive test battery: Domains and measures
Cognitive domain Measurea Test Batteryb
IQ Scaled scoree Block design WPPSI-3/WASI
Scaled scoree Similarities
Scaled scoree Vocabulary
Scaled scoree Matrix reasoning
Executive Functions Detectability CPT-2 Connor’s
Total Correct Auditory Attn NEPSY-2
Total Correct Concept Formation WJ-3 Cognitive
Total Correct Numbers CMS
Learning and Memory Total items recalled Word Listsc CMS
Total items recalled Dot Locationsc CMS
Processing Speed Standard scored Visual Match I/II WJ-3 Cognitive
Decision Speed WJ-3 Cognitive
Mood/Behavior Measure Scale Battery
Executive Functioning Raw score Global Executive Composite BRIEF Parent
Externalizing symptoms T score Externalizing BASC-2 PRS
Internalizing symptoms T score Internalizing BASC-2 PRS
Covariate Measure Test Battery
Parent IQ Scaled scoree Vocabulary WASI
Scaled scoree Matrix Reasoning
aZ score was calculated for each measure using mean and SD from the current study pooling all participants (N = 216) at both baseline and 18 month visits. For
domains with more than one test, the average was taken giving equal weight to each z score.
bCMS = Children’s Memory Scale (Cohen, 1997); CPT-2 = Continuous Performance Test, Second Edition (Connors, 1994); NEPSY-2 = Neuropsychological
Battery for Children, Second Edition (Korkman, Kirk, & Kemp, 2007); WJ-3 Cognitive = Woodcock-Johnson Test of Cognitive Abilities, Third Edition
(Woodcock, McGrew, &Mather, 2001); WPPSI3 = Wechsler Preschool and Primary Scales of Intelligence, Third Edition (Wechsler, 2002); WASI = Wechsler
Adult Scale of Intelligence (Wechsler, 1999); BRIEF = Behavior Rating Inventory of Executive Functions (Gioia, Isquith, Guy, & Kenworthy, 2000); BASCII
PRS = Behavior Assessment System for Children, Second Edition Parent Rating Scales (Reynolds & Kamphaus, 2004).
cSame version given regardless of age.
dAge-based standard score from WJIII Cognitive normative update (NU) sample.
eAge-based scaled score derived from Wechsler normative sample.
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(Washington University in St. Louis), and the results were
analyzed at the DirecNet Coordinating Center (Jaeb Center
for Health Research, Tampa, FL). The median (interquartile
range) duration between baseline testing and 18 months
testing was 18 months with range 15 to 23 months.
Statistical Methods
Raw scores were transformed to Z scores for each measure
using mean and SD from the current study pooling all parti-
cipants (N = 216) at baseline and 18-months as described in
the prior paper reporting baseline cognitive results (Manschot
et al., 2006; van den Berg et al., 2010). Note that some
measures administered at baseline were given outside of
standardized range to maintain consistency across both
timepoints and age range (Cato et al., 2014). Domain scores
were omitted in participants who did not complete all sub-
domain measures. Supplementary Table 1 summarizes
source test scores for T1D and control participants used to
produce domain Z scores for cognition, behavior and mood.
Repeated measure least squares regression models were used
to account for the possibility that outcomes from siblings may
be correlated. These models compared children with T1D
versus those without on each of the domains and subdomain
measures adjusting for age, gender, and parent IQ. The
parent-reported child depression score obtained from the
BASC 2 PRS was used as an additional covariate for sub-
domain analyses as presence of depressive symptoms can
have a deleterious effect on cognition (Murrough, Iacoviello,
Neumeister, Charney, & Iosifescu, 2011).
Primary outcome domains were pre-deﬁned as learning and
memory, executive functions, processing speed and IQ.
Secondary outcomes included parent ratings of executive
functioning, externalizing behavior symptoms and internaliz-
ing mood symptoms. For primary domains, the Hochberg step
up approach (Hochberg, 1988) was used to adjust the
threshold-deﬁning statistical signiﬁcance to account for
multiple comparisons. No formal correction for multiple
comparisons was made for the other secondary domains.
Within the T1D cohort, all glycated hemoglobin levels
since diagnosis, and those collected quarterly for 18-months,
were used to compute a life-long cumulative index of
hyperglycemia exposure based on average amount >6%
(HbA1CAUC6%) using the trapezoidal rule. Glycemic
variables from continuous glucose monitoring data included:
mean glucose (GluMean), percent time when glucose values
>180mg/dL, >250mg/dL, and <70mg/dL, standard devia-
tion (SD), and coefﬁcient of variation (CV). CGM indices
were calculated from data downloads at the enrollment visit
and each of the follow-up visits every 3 months through
18 months. The average CGM indices across all 7 visits for
each participant were calculated giving equal weight to each
visit. Participants who had 4 or fewer visits with at least 48 hr
of CGM data were not included in the analyses. Other
diabetes-speciﬁc variables included age of onset, duration of
diabetes, number of severe hypoglycemia events and DKA
events. Spearman partial correlations were conducted
between these variables and each of the cognitive domains,
adjusting for age, gender, and parent IQ. Only p-values below
.01 were considered statistically signiﬁcant.
RESULTS
Cross-sectional Data
Even though symptom improvement was noted over time, at
18 months T1D subjects still had signiﬁcantly more inter-
nalizing mood symptoms (p = .002) than controls, replicat-
ing what was observed at baseline. None of the cognitive
domains were signiﬁcantly different between the groups at
18 months (Figure 1).
Longitudinal Data
Both groups tended to improve on the cognitive testing as
expected with age but did not differ in degree of change over
18 months (Table 2). An inspection of within group changes
suggests the largest increase across both groups in learning
and memory, followed by executive functions. There was
also a modest differential increase in verbal IQ among the
T1D group. Level of internalizing mood symptoms improved
within the T1D group, although group differences remained
(see above).
Fig. 1. Estimated effect sizes for cognitive domains at 18 months.
The dot represents the point estimate and the width of the bars
represents a 99% conﬁdence interval. The conﬁdence intervals are
not otherwise corrected for multiple comparisons. For the domains
of Executive Functions, IQ, Learning and Memory, and
Processing Speed, effect sizes to the right of the vertical line
indicate that the control group scored higher. For BRIEF,
Externalizing and Internalizing domains, scores are reversed such
that effect sizes to the right of the vertical line indicate that the
control group had less symptoms.
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Relationship to Glycemic Variables
Mean HbA1c at the beginning and end of the study was 7.9%
(63mmol/mol). As measured by CGM data across the 7 visits
during the 18-month study, 50% of participants had glucose
levels >180mg/dL for >12 hr a day and >250mg for >6 hr a
day. Median time <70mg/dL was 66min per day and
<60mg/dL was 39min per day. Within the T1D group, CGM
measures did not correlate with change in cognitive domains
over 18 months (Table 3).
Table 2. Cognitive Outcomes Changes from Baseline to 18 Months
Changes (18 month–baseline)
T1D Control
N Mean± SD p-Valuea Mean± SD p-Valuea p-Valueb
Z- Scores
IQc 137/65 +0.27± 0.69 <.001 +0.13± 0.82 .21 .44
Verbal IQ 137/65 +0.22± 0.82 .002 +0.06± 0.98 .63 .46
Performance IQ 137/65 +0.16± 0.76 .02 +0.04± 0.78 .72 .89
Executive Functionsc 131/68 +0.77± 0.64 <.001 +0.65± 0.61 <.001 .68
Learning and Memoryc 137/66 +1.08± 0.65 <.001 +1.04± 0.66 <.001 .67
Processing Speedc 135/69 −0.10± 0.82 .14 −0.15± 0.86 .14 .50
BRIEF (Behavior Rating Inventory of Executive Function by Parent)d 140/67 −0.12± 0.82 .08 −0.21± 0.73 .02 .26
Externalizing (Behavior Assessment by Parent)d 142/68 −0.08± 0.84 .24 −0.03± 0.72 .71 .44
Internalizing (Behavior Assessment by Parent)d 142/67 −0.21± 0.77 .002 −0.04± 0.76 .68 .91
ap-values from paired t- test for within-group changes.
bNominal p-value uncorrected for multiple comparisons. Obtained from repeated measure least squares regression models, adjusted for baseline cognitive
scores, siblings from same family, age, gender, and parent IQ.
cPositive changes are better.
dPositive changes are worse.











Speed BRIEF Externalizing Internalizing
% Glucose in target range
(71–180mg/dL)
Spearman correlation +0.01 −0.10 +0.02 −0.15 −0.04 −0.09 +0.03 +0.06 −0.01
p-value .91 .30 .87 .10 .63 .35 .73 .47 .88
N 124 122 122 118 124 123 129 129 129
% Glucose in hypoglycemia
(<70mg/dL)
Spearman correlation +0.14 +0.05 +0.12 −0.00 +0.22 +0.01 −0.02 −0.11 −0.01
p-Value .12 .59 .18 .99 .01 .92 .84 .24 .94
N 124 122 122 118 124 123 129 129 129
% Glucose in hyperglycemia
(above 180mg/dL)
Spearman correlation −0.04 +0.07 −0.02 +0.14 −0.03 +0.08 −0.00 +0.00 +0.03
p-Value .68 .45 .81 .14 .74 .37 .97 .97 .77
N 124 122 122 118 124 123 129 129 129
Glucose coefﬁcient of
variation (SD/mean)
Spearman correlation +0.15 +0.04 +0.16 +0.02 +0.19 −0.01 −0.02 −0.06 −0.06
p-Value .10 .69 .08 .86 .04 .95 .79 .52 .50
N 124 122 122 118 124 123 129 129 129
Mean glucose
Spearman correlation −0.04 +0.07 −0.02 +0.14 −0.02 +0.12 −0.02 +0.00 +0.04
p-Value .65 .48 .84 .13 .86 .20 .83 .96 .67
N 124 122 122 118 124 123 129 129 129
aCGM indices are averaged values from baseline to 18 month. Spearman partial correlation controlled for age at 18 month testing, gender, and parent IQ, not
adjusted for multiple comparisons.
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There were two moderate DKA events and two DKA
events with unknown severity in four individuals between
baseline and 18 months and no known severe DKA events
during this time period. Eight SH events occurred in six
participants between baseline and 18 months, and one
seizure/coma event. The number of SH events that occurred
during the study did not correlate with changes in cognitive
domains in 18 months (Table 4). At 18 months, Verbal IQ
negatively correlated with number of DKA events before
18 months (r = −.23; p = .009). Within the T1D group,
additional data trends were observed including an inverse
relationship between hyperglycemia (averaged A1c AUC
above 6.0%) and executive functions (r = −.19; p = .03),
and an inverse relationship between number of DKA events
before 18 months and IQ (r = −.17; p = .05) as well as
executive functions (r = −.20; p = .02). There was also an
inverse relationship between Performance IQ at 18 months
and history of SH events (r = −.19; p = .04) (see Table 5).
We performed additional exploratory sub-group analyses to
determine if there were any interaction effects on cognitive
outcomes for exposure to glycemic extremes at an early age
and subsequent dysglycemia exposure, as proposed by Ryan
(2006). As this analysis was exploratory, we selected two
cognitive variables: VIQ and a combination of the three
executive functioning measures that best discriminated among
T1D and non-T1D participants in our cohort at baseline. To
test Ryan’s hypothesis, we examined whether moderate/
severe DKA around the time of diagnosis would interact with
subsequent greater exposure to hyperglycemia (deﬁned as
upper quartile in our T1D cohort for cumulative exposure) to
predict worse cognitive outcomes. Before examining the
impact of the combination of these risk factors, we looked at
each component separately within our T1D cohort.
Performance on executive functioning measures trended
lower for those T1D individuals (n = 32) with baseline history
of moderate to severe DKA (p = .03); mean differences were
also observed in this direction for VIQ but with p value of only
.09. Similarly, lower performance on executive functioning
measures (p = .02) was observed for those T1D individuals in
the upper quartile for hyperglycemia exposure, deﬁned as A1c
AUC≥11.2. The direction of themeanswas for worst Verbal IQ
for T1D participants in upper quartile but the mean difference
was not signiﬁcant (p = .12). Only nine participants experienced
both Severe/Moderate DKA at baseline and were in the upper
quartile of our T1D cohort for hyperglycemia exposure over the
18-month period (deﬁned as A1CAUC≥11.2). By examination
of mean performances, the small number of children with this
combination of risk factors fared the worst on the executive
functions measures, consistent with Ryan’s hypothesis.
However, among those with moderate/severe DKA history
Verbal IQ was not worst for those T1D cases also in the upper
quartile hyperglycemia group.
DISCUSSION
Differences in cognitive function between children with and
without T1D did not worsen over the course of 18 months in
this longitudinal study. In addition, children with T1D did not
differ from controls in the rate of change in cognitive function
over 18 months. In fact, comparable improvements in per-
formance over time were seen in both groups. Practice effects











Speed BRIEF Externalizing Internalizing
Averaged A1c AUC above
6.0% in 18 months
Spearman correlation +0.09 +0.11 +0.07 +0.05 −0.05 +0.14 +0.04 −0.06 +0.01
p-Value .30 .21 .44 .58 .55 .12 .66 .52 .95
N 133 131 131 127 133 131 136 138 138
# of SevHypo events in
18 months
Spearman correlation +0.01 +0.07 −0.12 −0.13 +0.03 −0.03 −0.06 +0.07 +0.04
p-Value .89 .44 .16 .14 .73 .70 .47 .41 .68
N 133 131 131 127 133 131 136 138 138
Diabetes duration at
18 months
Spearman correlation −0.02 −0.02 −0.04 +0.04 +0.01 0.00 +0.06 −0.01 +0.09
p-Value .84 .86 .65 .68 .89 .99 .52 .90 .32
N 133 131 131 127 133 131 136 138 138
Age at onset (yrs)
Spearman correlation −0.02 0.00 −0.02 −0.05 +0.01 −0.05 −0.07 +0.03 −0.06
p-Value .79 .96 .79 .56 .94 .59 .40 .72 .50
N 133 131 131 127 133 131 136 138 138
aSpearman partial correlation controlled for age at 18 month testing, gender, and parent IQ, not adjusted for multiple comparisons.
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may have enhanced the rate of improvement over and above
underlying developmental processes but did not appear to
differentially affect the groups. Regression to the mean, the
tendency for most extreme scores to normalize toward
distribution center over time, may also have come into play.
Even so, group performances at 18 month follow-up were
similar and indicated comparable cognitive functioning
across groups. This contrasts with the signiﬁcant differences
in gray and white matter regional volumes and overall brain
growth observed in this cohort as compared to controls
(Mauras et al., 2015).
This pattern of preserved cognitive function in the face of
structural growth differences between baseline and
18 months could suggest cerebral reserve in this young age
group. We know from other clinical populations that abnor-
mal changes in brain structure can precede clinical manifes-
tations. In Parkinson’s disease, it is well established that
depletion of dopaminergic cells in the substantia nigra must
reach a certain threshold before clinical problems are man-
ifest (Cato & Crosson, 2006). In multiple sclerosis, structural
and functional hippocampal changes have been observed
with intact memory function (Roosendaal et al., 2010). In
childhood epilepsy, children without impaired language
skills have been shown to have abnormal brain development
and reorganization of language-related brain regions (Caplan
et al., 2009). Hermann, Seidenberg, and Bell (2002) posit that
childhood onset temporal lobe epilepsy represents an early
acquired vulnerability that places patients at risk for
progressive cognitive decline, citing a reduction in cerebral
reserve over time in this chronic condition that has
established impact on both brain structures and function. In
the case of childhood onset T1D, long-term exposure to
dysglycemia may lead to sub-clinical neural changes that
accumulate until they become clinically relevant through
standardized cognitive and behavioral testing. Thus, the
possibility of delayed cognitive impact should be closely
monitored over time.
This is especially likely given what we already know about
cognition in childhood onset T1D and disease duration. In
several of the studies that report cognitive differences in T1D
patients with childhood onset disease, the cohorts were older
(teenagers) and/or had longer disease duration (Lin et al.,
2010; Northam, Anderson, Werther, Warne, & Andrewes,
1999; Perantie et al., 2008; Ryan et al., 1985). Speciﬁcally,
studies from the labs of E. Northam and T. Hershey, for
example, suggest that over longer disease duration, such as
12 years (Lin et al., 2010; Northam et al., 1999; Perantie
et al., 2008), risk factors of EOD, severe hypoglycemia, and
poor metabolic control (DKA and hyperglycemia) have an
additive and cumulative impact on cognition. Particularly in
the case of Verbal IQ and within the domain of Executive
Functions, long-term exposure to these risk factors are
associated with performance decrements relative to study
comparison groups.
In 2006, Ryan proposed that beyond duration of illness,
individuals with childhood onset T1D and a history of
chronic hyperglycemia, who then went on to experience
severe neuroglycopenia at any point thereafter may be parti-
cularly vulnerable to suffering cognitively. We similarly
explored this in our study and examined the interaction











Speed BRIEF Externalizing Internalizing
Averaged A1c AUC above
6.0%
Spearman correlation −0.13 −0.09 −0.08 −0.19 −0.01 +0.13 +0.10 +0.08 +0.13
p-Value 0.15 0.31 0.36 0.03 0.92 0.13 0.25 0.38 0.13
N 133 131 131 134 135 135 140 138 138
# of SevHypo events
Spearman correlation −0.14 −0.06 −0.19 −0.06 −0.08 +0.06 −0.04 −0.00 +0.01
p-Value 0.12 0.52 0.04 0.51 0.34 0.48 0.63 0.96 0.90
N 133 131 131 134 135 135 140 138 138
# of DKA eventsb
Spearman correlation −0.17 −0.23 −0.04 −0.20 −0.07 −0.14 +0.07 −0.03 +0.01
p-Value 0.05 0.009 0.63 0.02 0.44 0.12 0.40 0.75 0.91
N 131 129 129 133 133 133 138 136 136
Diabetes Duration
Spearman correlation +0.03 +0.04 −0.02 +0.02 −0.08 +0.03 −0.05 −0.01 −0.04
p-Value 0.69 0.64 0.79 0.82 0.36 0.71 0.59 0.91 0.65
N 133 131 131 134 135 135 140 138 138
Age at onset (yrs)
Spearman correlation −0.07 −0.05 −0.02 −0.03 +0.13 −0.11 +0.02 −0.02 +0.04
p-Value 0.46 0.57 0.85 0.76 0.14 0.23 0.81 0.85 0.68
N 133 131 131 134 135 135 140 138 138
aSpearman partial correlation controlled for age at 18 month testing, gender and parent IQ, not adjusted for multiple comparisons.
bExcluded 2 subjects with unknown DKA status.
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between history of moderate to severe DKA around the time
of diagnosis and subsequent exposure to a high degree of
chronic hyperglycemia over 18 months. We operationalized
highest exposure to cumulative hyperglycemia as upper
quartile of A1c AUC at 18 months. Consistent with Ryan’s
hypothesis, we found that those who performed lowest on
executive functioning measures was the subgroup of T1D
children with a history of DKA at diagnosis and greatest
cumulative exposure to hyperglycemia.
Within the adult literature, Nunley et al. (2015) found that
among middle-aged adult cases with history of childhood
onset T1D, individuals with over a 14-year history of average
A1c> 7.5%, demonstrated clinically relevant cognitive
impairment [odds ratio (OR) of 3.0]. Clinically relevant white
matter hyperintensities were also observed earlier relative to
non-T1D controls in middle-aged patients with childhood
onset T1D (Nunley et al., 2015). In a similar vein, (Weinstein
et al., 2015) reported that in a cohort of 1497 middle-aged
participants, diabetes and higher fasting BG were associated
with worse scores on cognitive measures, increased rate of
white matter hyperintensities and reductions in gray matter
densities and white matter integrity (measured by fractional
anisotropy). The issue of duration of illness and compound-
ing insults warrants additional investigation.
In this study, few patients evidenced new severe
hypoglycemia or DKA events over the 18 month period. This
may have underestimated the effect that either may have on
cognitive course. Indeed there were only four total DKA
events in four individuals between baseline and 18 months,
none of which were classiﬁed as severe. Only eight SH events
(only one with seizure/coma) occurred in six participants
(4%) between baseline and 18 months. In contrast, during the
12-year follow-up study by Northam and colleagues, 44% of
the type 1 diabetes group had one or more episodes of severe
hypoglycemia with seizure/coma (Lin et al., 2010; Northam
et al., 2009). From these prior papers, we know that severe
hypoglycemia can have an adverse impact on verbal ability,
working memory and processing speed.
Further limiting our study is the possibility that our
measures may not have been sufﬁciently sensitive. Most of
the cognitive measures were the same used at baseline. Our
T1D cohort is comprised of bright young children (average
VIQbaseline = 108; average PIQbaseline = 109) from edu-
cated parents (% parents postgraduate at baseline = 38%)
with high socioeconomic status (% ≥100K = 36%) for
whom test selection for subsequent time points has centered
on avoiding ceiling effects. Given our high functioning
groups, the lack of group differences could in part be
explained by excessive practice effects and near-ceiling
effects. To address these concerns, for timepoints 3 and 4
(both funded and underway), we have selected several alter-
native measures within the same domains.
Although we do not see clear group differences in our data
at this time, given what we know about cognition in child-
hood onset T1D following longer disease duration, it is likely
that as we continue to study this cohort over time, group
differences will emerge or subgroup differences will be more
clearly evident. Continued study of this cohort will clarify to
what extent persistent exposure to diabetes, dysglycemia, and
regional brain changes lead to measurable cognitive differ-
ences and whether these differences equate to clinically
meaningful deﬁcits. In particular, we will continue to exam-
ine impact of prolonged exposure to hyperglycemia over
time. Recent ﬁndings in the adult literature combined with
our ﬁndings provide a clear message that more scrupulous
control to guard against prolonged exposure to hyperglyce-
mia is needed, especially for those most vulnerable (those
with early childhood onset T1D).
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